CBL0137 for Cancer

"20 hospitals are currently involved with this study. Some locations include Children's Hospital of Philadelphia, Dana-Farber Cancer Institute, and Saint Jude Children's Research Hospital."

"This particular study is designed for patients aged 12 months to 30 years old. In contrast, there are 841 other studies available for patients under the age of 18 and 4728 for patients over the age of 65."

"This study is looking for 38 participants that have been diagnosed with cancer aged between 12 months and 30 years old. There are several key eligibility requirements that applicants must meet, which are as follows: Part A: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or known CNS metastases (including untreated or progressive) are eligible, Part B1 and B2: Patients must have measurable disease, Parts A and B1: Patients must be >= 12 months and =< 21 years of age at the time of study enrollment, Part B2 (relapsed/refractory osteosar"

"According to the website clinicaltrials.gov, the last update to this study was on 6/29/2022, which indicates that the trial is not actively recruiting patients. Although this is the case, there are 5263 other studies that are currently enrolling participants."

"The primary objective of this clinical trial, which will last for a maximum of 21 days, is to assess the anti-tumor effect of CBL0137 in children with diffuse intrinsic pontine glioma (DIPG) or other H3 K27M-mutant diffuse midline gliomas (Phase II). Secondary objectives include measuring the Area under the drug concentration curve of CBL0137, the Minimum serum concentration of CBL0137, and the Frequency of adverse events attributable to CBL0137."